LDE225
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Basal Cell Carcinoma
Conditions
Basal Cell Carcinoma
Trial Timeline
Jun 29, 2011 → Jun 29, 2018
NCT ID
NCT01327053About LDE225
LDE225 is a phase 2 stage product being developed by Novartis for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01327053. Target conditions include Basal Cell Carcinoma.
What happened to similar drugs?
1 of 7 similar drugs in Basal Cell Carcinoma were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02195973 | Phase 1 | Completed |
| NCT02151864 | Phase 1 | Completed |
| NCT02086513 | Phase 1 | Terminated |
| NCT02002689 | Phase 2 | Terminated |
| NCT01826214 | Phase 2 | Completed |
| NCT01764776 | Phase 1 | Completed |
| NCT01529450 | Pre-clinical | Completed |
| NCT01327053 | Phase 2 | Completed |
| NCT01125800 | Phase 1/2 | Completed |
| NCT01208831 | Phase 1 | Completed |
| NCT00880308 | Phase 1 | Completed |
Competing Products
20 competing products in Basal Cell Carcinoma